Barclays PLC Raises Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Barclays PLC grew its stake in AxoGen, Inc. (NASDAQ:AXGN) by 119.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 72,036 shares of the medical equipment provider’s stock after buying an additional 39,182 shares during the quarter. Barclays PLC owned 0.16% of AxoGen worth $1,010,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Geode Capital Management LLC lifted its position in shares of AxoGen by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock worth $14,170,000 after purchasing an additional 31,612 shares during the last quarter. State Street Corp raised its stake in AxoGen by 11.9% in the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock valued at $12,571,000 after buying an additional 95,051 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in AxoGen during the 3rd quarter worth about $240,000. Parkman Healthcare Partners LLC acquired a new position in shares of AxoGen during the 3rd quarter worth about $5,789,000. Finally, Verition Fund Management LLC increased its holdings in shares of AxoGen by 41.0% in the 3rd quarter. Verition Fund Management LLC now owns 40,860 shares of the medical equipment provider’s stock valued at $573,000 after acquiring an additional 11,874 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $15.00.

AxoGen Stock Performance

NASDAQ AXGN opened at $18.24 on Wednesday. The company has a fifty day moving average of $14.73 and a two-hundred day moving average of $12.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $18.49. The company has a market capitalization of $802.71 million, a PE ratio of -57.00 and a beta of 1.01.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.